ASCO GU 2024

Is "more" always better?

Combination vs. monotherapy - a great new option for high-risk patients

BRCAAway - practice changing or hypothesis generating data?

Cabo + IO: Interesting but not practice changing?!

BRCAaway - PARP combination study

Salvage radiation with anti-androgen superior to radiation alone

Enzalutamide therapy as option for biochemical recurrence

Therapy Intensification Still Neglected in mHSPC

Long-term dose escalation - Therapy in high-risk prostate cancers

Further testing before olaparib combination

Relugolix combined with androgen signaling in real word experience

First positive study of IO therapy in mCRPC

Higher radiation is effective in high-risk PCA

Combination NHT + PARP makes sense

Still a difficult time for androgenic inhibitors in mCRPC

Olaparib + Arbiraterone better compared to either alone

Insights and news for mCRPC

Localized PCa - news for radiotherapy and biochemical recurrence

Gleason 3+3 - cancer or not?

Dose de-escalation in different ways

Combination of cabozantinib & checkpoint inhibitor

What about the clinical benefit?

Evaluating the recombination-repair mutations in patients with mCRPC

Quality of life under intensive therapy

Cognitive function in ART treatment

Stockholm3 validated in multiethnic cohort

Kognitiv påverkan av abirateron och enzalutamid?

BRCAAway - PARP hämmare, abiraterone eller i kombination

Kombination av cabozantinib och immunterapi

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

Gleason 3+3 ska vi kalla de cancer eller inte?

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

New standard of care, but still open questions!

Advances in (neo)-adjuvant treatment in urothelial cancer

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder cancaer patients

MIBC: adjuvant PD1 - all set?!

EV as standard in 3rd line mUC

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Highlights in bladder cancer at ASCO GU24

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Perioperative adjuvant therapy in urothelial cancer

Update M1 urothelial cancer

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

HER2 and bladder cancer

ASCO GU24 - Highlights in Bladder cancer

EV + Pembro new first-line standard in localized metastatic bladder cancer

Update on EV-302

Biomarker update

Pembrolizumab adjuvant in bladder cancer

Another success for an ICI?

Encore un succès pour une ICI ?

Novedades sobre EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Terapia adyuvante perioperatoria en el cáncer de vejiga

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Subcutaneous vs. intravenous application: ready for everyday clinics?

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

No surprise with the QoL data

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Perioperative treatment in renal cell carcinoma - did we close the circle?

Better QoL with Belzutifan

Durable effects of Ipi-Nivo

Long-term follow-up of first-line trials

Tumorburden and outcome

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Overall survival benefit - Pembro after surgery

Practice changing adjuvant therapy?!

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Highlights in kidney cancer at ASCO GU24

ASCO GU24 - Highlights in renal cell carcinoma

Long-Term Data on NIVO+IPI in aRCC

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Long-term outcome

Belzutifan: Updates on QoL

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?